Saturday 17 October 2026
Export SLDB’s income statement to Excel — free account
Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.
5.53
0.21
−3.66%
Follow SLDB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.50 | 5.65 | 12.59 | 13.24 | |
Current Ratio |
6.74 | 6.14 | 13.10 | 13.82 | |
Net Debt/EBITDA |
4.92 | 3.81 | 6.63 | 6.48 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 1.08 | 0.83 | 0.96 | |
Capex/Depreciation |
(1.73) | 1.71 | 0.74 | 0.15 | |
Interest Coverage |
143.03 | (9,880.60) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.35) | (0.61) | (0.43) | (0.37) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.36) | (0.62) | (0.43) | (0.37) | |
Cash per Share |
2.50 | 2.16 | 3.47 | 2.63 | |
Shareholders Equity per Share |
2.31 | 2.06 | 3.41 | 2.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.31 | 2.06 | 3.41 | 2.60 | |
Free Cash Flow |
(33.56) | (54.03) | (47.39) | (52.74) | |
Working Capital |
208.51 | 171.98 | 366.51 | 366.52 | |
Capital Expenditures |
(0.08) | (0.48) | (0.16) | (0.15) | |
Net Current Asset Value |
188.89 | 152.93 | 348.03 | 348.60 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.94 | 3.73 | 6.00 | 4.53 | |
Average Assets |
242.87 | 210.60 | 383.40 | 364.44 | |
Average Common Equity |
192.49 | 158.63 | 334.30 | 316.18 |
Columns are period end dates